Can-Fite BioPharma (CANF) announced it received a Notice of Allowance from the National Institute of Industrial Property of Brazil for its patent application titled “An A3 Adenosine Receptor Ligands For Use in Treatment of a Sexual Dysfunction”. The invention addresses the use of Can-Fite’s CF602 drug candidate as an oral or topical treatment for erectile dysfunction, ED, patients living with diabetes and those who are non-responders to ED drugs currently on the market.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- CANF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Why Is Can-Fite BioPharma Stock (CANF) Up Today?
- Can-Fite Achieves 9-Year Survival Milestone in Liver Cancer Treatment
- Can-Fite announces 9-year survival with complete cure with Namodenoson